Amwell CEO Roy Schoenberg to Speak at Stanford Disability & Telehealth Conference Amwell CEO to join tech and health leaders from Apple, Stanford Health and others in discussing virtual care solutions that bolster accessibility Boston, May 16, 2024 (GLOBE NEWSWIRE) -- ® (NYSE: AMWL), a leader in hybrid care enablement, today announced its Co-CEO and President, Roy Schoenberg, M.D., M.P.H., will speak at the at 12:15 PST on Saturday, May 18. The virtual conference explores barriers to telehealth enhancement for those with disabilities and the innovative solutions underway to advance hea...
Texas Capital Bancshares, Inc. Appoints Mark Midkiff to Board of Directors DALLAS, May 16, 2024 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced the appointment of Mark Midkiff to its Board of Directors, effective June 1, 2024. Midkiff will also serve as a member of the Board’s Risk Committee. Midkiff brings nearly three decades of experience to Texas Capital. Most recently, Midkiff served as chief risk officer at KeyCorp where he reported directly to the CEO. In this role, he oversaw comprehensive risk management fun...
Texas Capital Appoints Steve Genyk to Lead New Public Finance Practice DALLAS, May 15, 2024 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced that Steve Genyk has joined Texas Capital Securities (TCS), Texas Capital’s broker dealer subsidiary, as Managing Director, Head of Public Finance. In this new role, Genyk is responsible for building out TCS’s Public Finance business, which will provide municipal underwriting services to governments, nonprofits and institutions in the state of Texas and across the country. Ge...
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update Completed dosing in cohort one (low dose, 5.7x1014 total vg) of REVEAL Phase 1/2 adolescent and adult trial with longer-term data supporting the safety profile and durable response of TSHA-102; enrolled first patient in cohort two (high dose, 1x1015 total vg) with dosing scheduled for Q2 2024 Dosed second pediatric patient in cohort one (low dose, 5.7x1014 total vg) of REVEAL Phase 1/2 pediatric trial in Q1 2024 FDA granted Regenerative Medicine Advanced Therapy designation fol...
RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares ALISO VIEJO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc. (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it has closed its underwritten public offering of 2,053,571 shares of its common stock, at a price to the public of $56.00 per share, which includes the full exercise by the underwriters of their option to purchase u...
RxSight, Inc. Announces Pricing of Public Offering of Common Stock ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it has priced its underwritten public offering. RxSight expects to sell 1,785,714 shares of its common stock at a price to the public of $56.00 per share. RxSight has granted the underwriters a 30-day option to purchase up to an additional 267,857 shares of its common stock at the public...
RxSight, Inc. Announces Proposed Public Offering of Common Stock ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock in an underwritten public offering. In addition, RxSight expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered...
Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14 DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2024, and host a corporate update conference call and webcast on Tuesday, May 14, 2024, at 4:30 PM Eastern T...
Texas Capital Foundation Announces Second Annual Honors Awards Grant Recipients Grants totaling $250,000 will support four Texas nonprofit organizations DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced the recipients of the Texas Capital Foundation’s second annual Honors Awards. The awards provide grants totaling $250,000 to support four nonprofit organizations addressing community needs across Texas. The Honors Awards are a signature program of the Texas Capital Foundation, which Texas Capital ...
RxSight, Inc. Reports First Quarter 2024 Financial Results ALISO VIEJO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2024. Key Quarterly Highlights Reported first quarter 2024 revenue of $29.5 million, an increase of 69% compared to the first quarter of 2023, reflecting: The sale of 20,218 Light Adjustable Lenses (LAL®/LAL+™), representing a 92% ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, May 03, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that, on May 1, 2024, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, options to purchase 528,000 shares of the Company's common stock in connection with their emp...
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL Phase 1/2 trials (adolescent/adult and pediatric) RMAT designation enables increased dialogue with the FDA to support the potential expedited development and review of TSHA-102 in clinical evaluation for Rett syndrome DALLAS, May 02, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Na...
RxSight, Inc. to Present at the Bank of America Healthcare Conference ALISO VIEJO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference. RxSight’s management is scheduled to present on Wednesday, May 15, 2024, at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: . About RxSight, Inc. ...
AMWELL ANNOUNCES RESULTS FOR FIRST QUARTER 2024 Boston, May 01, 2024 (GLOBE NEWSWIRE) -- (NYSE: AMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the first quarter ended March 31, 2024. Visit Amwell’s investor relations website at to view the first quarter 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Wednesday, May 1. The call can be accessed via a live audio webcast at or by dialing 1-888-510-2008 for U.S. participants or...
Sound Financial Bancorp, Inc. Q1 2024 Results SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Sound Financial Bancorp, Inc. (the "Company") (Nasdaq: SFBC), the holding company for Sound Community Bank (the "Bank"), today reported net income of $770 thousand for the quarter ended March 31, 2024, or $0.30 diluted earnings per share, as compared to net income of $1.2 million, or $0.47 diluted earnings per share, for the quarter ended December 31, 2023, and $2.2 million, or $0.83 diluted earnings per share, for the quarter ended March 31, 2023. The Company also announced today that its Board of D...
Amwell Releases 2024 Corporate Responsibility Report Report demonstrates company progress toward enabling digital healthcare with purpose Boston, April 29, 2024 (GLOBE NEWSWIRE) -- ® (NYSE: AMWL), a leader in hybrid care enablement, today announced the release of its 2024 Corporate Responsibility Report, which details the company’s latest progress across environmental, social, and governance (ESG) topics and highlights Amwell’s growing positive impact on key stakeholders and the communities it serves. “Corporate responsibility is fundamental to our mission to transform healthcare, wh...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.